Evidence map›Paper›PMID 38064591›Full record

ArticleMedical physics2024

Intraprocedural C-arm dual-phase cone-beam enhancement patterns correlate with tumor absorbed dose after radioembolization.

Remco Bastiaannet, MingDe Lin, Eric C Frey, Hugo W A M de Jong

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Medical physics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01177007 (Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 66% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01177007 phase2completednot on this map

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

TypeinterventionalSponsorYale UniversityRan2010 to 2014Enrolled50ConditionsLiver NeoplasmsArmsTheraSphere, Yttrium-90 glass Microspheres
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Remco BastiaannetThe Russell H Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0001-7056-3229
MingDe LinDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, USA.
Eric C FreyThe Russell H Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Hugo W A M de JongDepartment of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Johns Hopkins University · USUniversity Medical Center Utrecht · NLYale University · US

Funding

See, Reach, Treat Tumor-Optimized Transarterial Chemoembolization DrugDeliveryR01CA160771 · NCI · YALE UNIVERSITY · PI GESCHWIND, JEAN-FRANCOIS H, LIN, MINGDE · 2011 to 2015
$2.6M
SBIR PHASE I TOPIC 392: TARGETED RADIONUCLIDE THERAPY OF METASTATIC LIVER CANCER: PATIENT SPECIFIC OPTIMIZATION75N91019C00047 · NCI · RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLC · PI GHALY, MICHAEL · 2019 to 2019
$299k
NCI NIH HHS 75N91019C00047NCI NIH HHS R01 CA160771
6 · The paper itself

Abstract

backgroundRecent studies have shown a clear relationship between absorbed dose and tumor response to treatment after hepatic radioembolization. These findings help to create more personalized treatment planning and dosimetry. However, crucial to this goal is the ability to predict the dose distribution prior to treatment. The microsphere distribution is ultimately determined by (i) the hepatic vasculature and the resulting blood flow dynamics and (ii) the catheter position. PURPOSE: To show that pretreatment, intra-procedural imaging of blood flow patterns, as quantified by catheter-directed intra-arterial contrast enhancement, correlate with posttreatment microsphere accumulation and, consequently, absorbed dose. MATERIALS AND

methodsPatients who participated in a clinical trial (NCT01177007) and for whom both a pretreatment dual-phase contrast-enhanced cone-beam CT (CBCT) and a posttreatment 90Y PET/CT scan were available were included in this retrospective study. Tumors and perfused volumes were manually delineated on the CBCT by an experienced radiologist. The mean, sum, and standard deviation of the voxels in each volume were recorded. The delineations were transferred to the PET-based absorbed dose maps by coregistration of the corresponding CTs. Linear multiple regression was used to correlate pretreatment CBCT enhancement to posttreatment 90Y PET/CT-based absorbed dose in each region. Leave-one-out cross-validation and Bland-Altman analyses were performed on the predicted versus measured absorbed doses.

resultsNine patients, with a total of 23 tumors were included. All presented with hepatocellular carcinoma (HCC). Visually, all patients had a clear correspondence between CBCT enhancement and absorbed dose. The correlation between CBCT enhancement and posttherapy absorbed tumor dose based was strong (R

conclusionThere is a linear relationship between pretreatment blood dynamics in HCC tumors and posttreatment absorbed dose, which, if shown to be generalizable, allows for pretreatment tumor absorbed dose prediction.

Indexed as

Carcinoma, HepatocellularEmbolization, TherapeuticLiver NeoplasmsHumansMicrospheresPositron Emission Tomography Computed TomographyRetrospective StudiesYttrium RadioisotopesYttrium-90Yttrium Radioisotopescone‐beam CTcontrast‐enhancementdosimetryperfusionradioembolization

Identifiers

PMID38064591
PMCPMC10994751
OpenAlexW4389490670

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.